{"schema":"pith.reference-change-event.v1","doi":"10.1016/s1470-2045(17)30074-8","canonical_url":"https://pith.science/event/10.1016/s1470-2045(17)30074-8","json_url":"https://pith.science/event/10.1016/s1470-2045(17)30074-8.json","not_a_judgment":"This page records that a citing paper's bibliography includes a work with a published notice. It is not a judgment on the citing paper.","primary":{"event_id":391184,"doi":"10.1016/s1470-2045(17)30074-8","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2019-04-30","title":"Correction to Lancet Oncol 2017; 18: e143–52","work_title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","work_doi":"10.1016/s1470-2045(17)30074-8","work_arxiv_id":null,"notice_doi":"10.1016/s1470-2045(19)30240-2","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s1470-2045(17)30074-8","json_href":"/event/10.1016/s1470-2045(17)30074-8.json"},"events":[{"event_id":391184,"doi":"10.1016/s1470-2045(17)30074-8","event_type":"correction","event_type_label":"Correction","source":"crossref","source_label":"Crossref","event_date":"2019-04-30","title":"Correction to Lancet Oncol 2017; 18: e143–52","work_title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","work_doi":"10.1016/s1470-2045(17)30074-8","work_arxiv_id":null,"notice_doi":"10.1016/s1470-2045(19)30240-2","flag_count":0,"flags_open":0,"flags_disputed":0,"latest_flag_at":null,"human_href":"/event/10.1016/s1470-2045(17)30074-8","json_href":"/event/10.1016/s1470-2045(17)30074-8.json"}],"flags":[{"id":8482,"status":"open","status_label":"Open","citing_arxiv_id":"2509.04939","citing_title":"The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors","ref_index":3,"evidence_raw":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8","evidence_cleaned":null,"evidence_source_label":"bibliography line","event_type":"correction","event_type_label":"Correction","source_label":"Crossref","event_date":"2019-04-30","work_title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","work_doi":"10.1016/s1470-2045(17)30074-8","event_doi":"10.1016/s1470-2045(17)30074-8","flag_href":"/flags/8482","event_href":"/event/10.1016/s1470-2045(17)30074-8","paper_href":"/paper/2509.04939","created_at":"2026-08-05T06:18:32.709950Z","dispute_note":null,"disputed_at":null,"disputed_by":null}],"flag_count":1,"flags_open":1,"flags_disputed":0,"desk_url":"https://pith.science/flags"}